Subscribe to RSS

DOI: 10.1055/s-0042-1750195
24-Hour Blood Pressure Control with Amlodipine: A Review of the Current Scenario
Funding None.
Abstract
Introduction Hypertension is the leading cause of cardiovascular diseases and premature death worldwide. Antihypertensive therapy using calcium channel blockers (CCBs) is one of the preferred choices to treat blood pressure (BP) and control blood pressure variability (BPV). In contrast to clinic BP, 24-hour ambulatory BP monitoring (ABPM) has evolved into an accurate and reproducible tool for the assessment and management of hypertension. Amlodipine, a longer acting dihydropyridine CCB is effective for 24 hours BP control and also minimizing BPV. The present article is the comprehensive review highlighting the efficacy of amlodipine in controlling 24-hour BP and minimizing BPV from the review of recent studies.
Materials and Methods The literature search was done using PubMed, Google Scholar, and MEDLINE databases. The studies to be included for review, were identified through the keywords: “amlodipine,” “ambulatory BP monitoring (ABPM),”“blood pressure variability (BPV),” “CCBs,” and filtering articles published in English language only.
Results Pharmacological evidence suggests that amlodipine has the ability to block all the subtypes of CCBs such as L-, N-, P-, Q-, R-, and T-type. Various clinical studies reported that amlodipine is a powerful, well-tolerated, and safe antihypertensive agent which is widely used either alone or as a key component of combination therapy for control of 24 hours BP.
Conclusion Overall, amlodipine is a proven and effective antihypertensive drug and helpful in controlling 24-hour BP, minimizing BP variability and hence reducing the risk of cardiovascular complications.
Data Availability Statement
All the relevant data have been represented in the manuscript. Any additional data can be provided by authors on reasonable request.
Publication History
Article published online:
01 June 2022
© 2022. Official Publication of The Simulation Society (TSS), accredited by International Society of Cardiovascular Ultrasound (ISCU). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Bulsara KG, Cassagnol M. Amlodipine. StatPearls; 2020
- 2 Gakidou E, Afshin A, Abajobir AA. et al; GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390 (10100): 1345-1422
- 3 Sarki AM, Nduka CU, Stranges S, Kandala NB, Uthman OA. Prevalence of hypertension in low-and middle-income countries: a systematic review and meta-analysis. Medicine (Baltimore) 2015; 94 (50) e1959
- 4 Ramakrishnan S, Zachariah G, Gupta K. et al; CSI-Great India BP Campaign Investigators. Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. Indian Heart J 2019; 71 (04) 309-313
- 5 Poudel B, Yadav BK, Nepal AK, Jha B, Raut KB. Prevalence and association of microalbuminuria in essential hypertensive patients. N Am J Med Sci 2012; 4 (08) 331-335
- 6 Banegas JR, López-García E, Dallongeville J. et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32 (17) 2143-2152
- 7 Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management?. Int J Cardiol 2018; 254: 328-332
- 8 Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006; 20 (03) 169-175
- 9 Douma LG, Gumz ML. Circadian clock-mediated regulation of blood pressure. Free Radic Biol Med 2018; 119: 108-114
- 10 Myers MG, Tobe SW, McKay DW. et al. New Algorithm for the Diagnosis of Hypertension: Canadian Hypertension Education Program Recommendations. Oxford University Press; 2005
- 11 Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 2012; 30 (03) 449-456
- 12 Niiranen TJ, Hänninen M-R, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension 2010; 55 (06) 1346-1351
- 13 Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day. Accessed on June 04, 2020 at: https://clinicaltrials.gov/ct2/show/results/NCT00700271
- 14 Reeves RA. The rational clinical examination. Does this patient have hypertension? How to measure blood pressure. JAMA 1995; 273 (15) 1211-1218
- 15 Rao D. Trends in Hypertension. Elsevier; 2012
- 16 Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10 (03) 143-155
- 17 Motoki H, Koyama J, Izawa A. et al. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography 2014; 31 (10) 1230-1238
- 18 Yilmaz R, Altun B, Kahraman S, Ozer N, Akinci D, Turgan C. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Ren Fail 2010; 32 (08) 903-912
- 19 Dolan E, Stanton AV, Thom S. et al; ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients–an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009; 27 (04) 876-885
- 20 Hara A, Tanaka K, Ohkubo T. et al. Ambulatory versus home versus clinic blood pressure: the association with subclinical cerebrovascular diseases: the Ohasama Study. Hypertension 2012; 59 (01) 22-28
- 21 Staessen JA, Thijs L, Fagard R. et al; Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282 (06) 539-546
- 22 Hodgkinson J, Mant J, Martin U. et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ 2011; 342: d3621
- 23 Parati G, Ochoa JE, Bilo G. Blood pressure variability, cardiovascular risk, and risk for renal disease progression. Curr Hypertens Rep 2012; 14 (05) 421-431
- 24 Höcht C. Blood pressure variability: prognostic value and therapeutic implications. ISRN hypertension. 2013
- 25 Parati G, Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. Hypertens Res 2014; 37 (03) 187-193
- 26 Fares H, DiNicolantonio JJ, O'Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart 2016; 3 (02) e000473
- 27 Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol 2017; 8: 286
- 28 Burges RA. Amlodipine: a once daily calcium antagonist. J Hum Hypertens 1991; 5 (Suppl. 01) 49-54
- 29 Lund-Johansen P, Omvik P, White W. et al. Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. Cardiology 1992; 80 (Suppl. 01) 37-45
- 30 Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 2011; 58 (02) 155-160
- 31 Deanfield JE, Detry J-MR, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24 (06) 1460-1467
- 32 Wang J-G, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens 2014; 8 (05) 340-349
- 33 Burris JF, Allenby KS, Mroczek WJ. The effect of amlodipine on ambulatory blood pressure in hypertensive patients. Am J Cardiol 1994; 73 (03) 39A-43A
- 34 Lacourcière Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens 2011; 25 (10) 615-622
- 35 Rizzoni D, Paini A, De Ciuceis C, Agabiti-Rosei C, Salvetti M. The smoothness index: an ‘all purposes’ approach to the assessment of the homogeneity of 24-h blood pressure control?. J Hypertens 2019; 37 (12) 2341-2344
- 36 Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens 2010; 28 (11) 2177-2183
- 37 Gorbunov VM, Smirnova MI, Deev AD. Assessment of amlodipine antihypertensive effect homogeneity in controlled trial. Ration Pharmacother Cardiol 2009; 5 (02) 22-26
- 38 Cho EJ, Lee HY, Sung KC. et al. Comparison of 24-hour ambulatory central blood pressure reduction efficacy between fixed amlodipine or up-titrated hydrochlorothiazide plus losartan: the K-central study. Am J Hypertens 2019; 32 (10) 992-1002
- 39 Huang QF, Sheng CS, Li Y. et al; Amlodipine Morning Blood Pressure Surge Study (ARMORS) Investigators. A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension. J Clin Hypertens (Greenwich) 2019; 21 (05) 648-657
- 40 Kotchen TA. Developing hypertension guidelines: an evolving process. Am J Hypertens 2014; 27 (06) 765-772
- 41 Sharma A, Bagchi A, Kinagi SB, Sharma YK, Baliga VP, Bollmall C. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007; 29 (12) 2667-2676
- 42 Aronow WS. Hypertension and left ventricular hypertrophy. Ann Transl Med 2017; 5 (15) 310
- 43 Adalet K, Mercanoǧlu F, Orak E. et al. The effect of amlodipine on the mass and functions of the left ventricle in patients with primary hypertension and left ventricular hypertrophy. Curr Ther Res Clin Exp 1995; 56 (06) 607-616
- 44 Packer M, O'Connor CM, Ghali JK. et al; Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335 (15) 1107-1114
- 45 Pitt B, Byington RP, Furberg CD. et al; PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102 (13) 1503-1510
- 46 Weber MA, Julius S, Kjeldsen SE. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363 (9426): 2049-2051
- 47 Nissen SE, Tuzcu EM, Libby P. et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292 (18) 2217-2225
- 48 Hwang YC, Yoon KH, Cha BS. et al. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-a randomized, open-label, active-controlled, superiority, parallel-group clinical trial. Int J Clin Pract 2017; 71 (09) e12987
- 49 Reams GP, Lau A, Hamory A, Bauer JH. Amlodipine therapy corrects renal abnormalities encountered in the hypertensive state. Am J Kidney Dis 1987; 10 (06) 446-451
- 50 Kumagai H, Hayashi K, Kumamaru H, Saruta T. Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens 2000; 13 (09) 980-985
- 51 Chan L, Chen C-H, Hwang J-J. et al. Cost-effectiveness of amlodipine compared with valsartan in preventing stroke and myocardial infarction among hypertensive patients in Taiwan. Int J Gen Med 2016; 9: 175-182
- 52 de Portu S, Mantovani LG. Amlodipine: a pharmacoeconomic review. J Med Econ 2009; 12 (01) 60-68
- 53 Wu Y, Zhou Q, Xuan J. et al. A cost-effectiveness analysis between amlodipine and angiotensin ii receptor blockers in stroke and myocardial infarction prevention among hypertension patients in China. Value Health Reg Issues 2013; 2 (01) 75-80
- 54 Limaye D, Kale M, Chitre N. et al. Cost-effectiveness study of antihypertensive drugs in Mumbai, India. Int J Life Sci Pharma Res 2018; 8 (01) 97-103
- 55 Weber MA, Schiffrin EL, White WB. et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014; 16 (01) 14-26
- 56 Das AK, Chatterjee S, Pal J. Clinical effectiveness and safety of low cost versus innovator brand amlodipine in hypertension: a single-blinded, randomized, crossover, noninferiority trial. Indian J Pharmacol 2016; 48 (06) 706-709
- 57 Bramlage P, Wolf W-P, Fronk E-M. et al. Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care. Expert Opin Pharmacother 2010; 11 (17) 2779-2790
- 58 Marques da Silva P, Haag U, Guest JF, Brazier JE, Soro M. Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Health Qual Life Outcomes 2015; 13 (01) 24
- 59 Dasgupta K, Quinn RR, Zarnke KB. et al; Canadian Hypertension Education Program. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014; 30 (05) 485-501
- 60 Parati G, Stergiou GS, Asmar R. et al; ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26 (08) 1505-1526
- 61 Luehr D, Woolley T, Burke R. et al. Hypertension diagnosis and treatment. Blood Pressure 2012; 140 (90) 90
- 62 Ogihara T, Kikuchi K, Matsuoka H. et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32 (01) 3-107
- 63 James PA, Oparil S, Carter BL. et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (05) 507-520
- 64 Stergiou GS, Palatini P, Asmar R. et al; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability Teaching Course Proceedings. Blood pressure monitoring: theory and practice. Blood Press Monit 2018; 23 (01) 1-8
- 65 Shimada K, Imai Y, Kario K. et al; JCS Joint Working Group. Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring (ABPM) (JCS 2010): digest version. Circ J 2012; 76 (02) 508-519
- 66 Myers MG, Haynes RB, Rabkin SW. Canadian Hypertension Society Guidelines for Ambulatory Blood Pressure Monitoring. Oxford University Press; 1999
- 67 Head GA, McGrath BP, Mihailidou AS. et al. Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. J Hypertens 2012; 30 (02) 253-266
- 68 Silke B, Verma SP, Zezulka AV. et al. Haemodynamic and radionuclide effects of amlodipine in coronary artery disease. Br J Clin Pharmacol 1990; 29 (04) 437-445
- 69 Broadhurst P, Heber ME, Brigden G, al-Khawaja I, Raftery EB. Intra-arterial monitoring of the antihypertensive effects of once-daily amlodipine. J Hum Hypertens 1992; 6 (Suppl. 01) S9-S12
- 70 Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs 2009; 9 (03) 135-142
- 71 El-Etriby AMK, Rakha S. Efficacy and safety of amlodipine/valsartan/hydrochlorothiazide single pill combination in Egyptian patients with hypertension uncontrolled on any dual therapy: an observational study. Curr Med Res Opin 2020; 36 (04) 537-544
- 72 Dharapur PM, Patil KA. A comparative study of the efficacy of cilnidipine and amlodipine used for the treatment of hypertension at tertiary health-care center. Natl J Physiol Pharm Pharmacol 2019; 9 (05) 454-458
- 73 Nwachukwu DC, Eze AA, Nwachukwu NZ. et al. Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: comparison of their efficacy and effects on electrolytes. Malawi Med J 2017; 29 (02) 108-112